register

News & Trends - Pharmaceuticals

Mental health pharmacy trial on track to commence

Health Industry Hub | August 3, 2020 |

Pharma News: The Pharmacy Guild of Australia (Guild), Pharmaceutical Society of Australia (PSA), Griffith University (GU) and The University of Sydney (USYD) are pleased to announce that The Bridging the Gap between Physical and Mental Illness in Community Pharmacy (PharMIbridge) trial is set to commence in a few months’ time.

This study, co-led by highly respected pharmacy and mental health researchers Professor Amanda Wheeler (GU) and Dr Claire O’Reilly (USYD), focuses on individualised medicine support, adherence and mental and physical wellbeing for people living with severe and persistent mental illness such as schizophrenia, bipolar and severe depression.

The National President of the Pharmacy Guild, George Tambassis, said community pharmacists were playing an increasingly important role in the area of mental health.

“As the most accessible of all health professionals, community pharmacists are often the first people mental health patients turn to for help and advice.  Many pharmacists have undergone additional training to help them identify patients who may be suffering mental illness.

“Pharmacists also are critical in helping patients adhere to their medicine regimens to ensure they  get best possible outcomes from the medicines they have been prescribed.

“This project is an exciting and important initiative to broaden the role of pharmacists in helping patients with mental illness.”

Pharmaceutical Society of Australia National President Associate Professor Chris Freeman said as medicines experts, pharmacists play a vital role in treating mental illness in the community.

“Medicines are an important component of treatment for people living with mental illness which is why pharmacists, as medicines experts, have a critical role to play, however that should not limit our role,” he said.

“Pharmacists serve as a critical element in the healthcare team, working with patients to manage their conditions, often as a conduit to other services, an advocate for the person, or to lend a compassionate ear.”

The RCT will be conducted in four study regions: Hunter New England and Northern Sydney regions in NSW, Gippsland region in Victoria, and ACT. Participating community pharmacies will be remunerated to support training attendance and to deliver either the PharMIbridge (intervention) or study funded MedsCheck (comparator) service.


News & Trends - MedTech & Diagnostics

$54 million cancer centre opens in one of Australia’s fastest growing communities

Health Industry Hub | March 28, 2024 |

MedTech & Diagnostics News: Cancer care provider, GenesisCare, is now treating patients at a new $54 million integrated cancer centre […]

More


Marketing & Strategy

Bayer, MSD and Takeda among winners at Asia Pacific awards

Bayer, MSD and Takeda among winners at Asia Pacific awards

Health Industry Hub | March 28, 2024 |

Bayer, MSD, Takeda, Alcon, and Cipla emerge as winners among this week’s announcements of Asia Pacific awards which celebrate organisations […]

More


News & Trends - MedTech & Diagnostics

Queensland elevates diagnostic precision with cutting-edge imaging technology

Queensland elevates diagnostic precision with cutting-edge imaging technology

Health Industry Hub | March 28, 2024 |

MedTech & Diagnostics News: Mackay Base Hospital and Qscan Mackay have unveiled state-of-the-art medical imaging machines to elevate patient care […]

More


News & Trends - Pharmaceuticals

Landmark collaboration sparks inauguration of precision care clinic

Landmark collaboration sparks inauguration of precision care clinic

Health Industry Hub | March 28, 2024 |

Pharma News: In a landmark collaboration, Australians with cancer will receive more personalised care through the newly established Precision Care […]

More


This content is copyright protected. Please subscribe to gain access.